Acutus Medical, Inc.

As of November 12, 2020, Acutus Medical, Inc. is considered overvalued and risky due to negative financial metrics, including a P/E ratio of 0 and a year-to-date return of -99.27%, significantly underperforming the S&P 500's 12.22% return.

Acutus Medical, Inc. is currently considered "risky" and overvalued due to negative financial metrics, including a P/E ratio of 0.0658 and significant underperformance with a year-to-date return of -94.0%, making it a less compelling investment compared to its peers.

As of June 9, 2025, the market trend is mildly bearish due to bearish weekly MACD and KST indicators, despite some mildly bullish signals on the monthly charts, indicating limited recovery potential and overall cautious sentiment.

As of March 2022, the management team of Acutus Medical, Inc. includes Executive Chairman R. Scott Huennekens, President and CEO Vince Burgess, and several Independent Directors: Dr. David Bonita, Dr. Andrew ElBardissi, Mr. Jim Hinrichs, Dr. Shahzad Malik, and Dr. Shaden Marzouk. They oversee the company's strategic direction and operations.

Acutus Medical, Inc. is a micro-cap company specializing in arrhythmia management by designing and marketing tools for catheter-based ablation procedures. As of December 2024, it reported net sales of $7 million and a net profit of -$1 million.

As of Jun 18, Acutus Medical, Inc. has a market capitalization of 0.07 million and reported net sales of 20.15 million with a net profit of -4.55 million over the last four quarters. Shareholder's funds are at -11.59 million, and total assets amount to 28.65 million.